New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:07 EDTADMSAdamas Pharmaceuticals initiates Phase 3 trial for ADS-5102
Adamas Pharmaceuticals announced that it has initiated a pivotal Phase 3 clinical study of ADS-5102, a high-dose, controlled-release version of amantadine for the treatment of patients with Parkinson's disease who have developed levodopa-induced dyskinesia. LID is a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. The Phase 3 study will enroll approximately 130 patients. It is a 26-week multi-center, randomized, double-blind, placebo-controlled trial, which will assess the efficacy of a once daily 340 mg dose of ADS-5102 administered at bedtime for the treatment of LID in individuals with Parkinson's disease. The primary endpoint of EASE LID is a reduction in LID as assessed by changes in the Unified Dyskinesia Rating Scale along with supporting data from secondary endpoints.
News For ADMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
06:05 EDTADMSAdamas Pharmaceuticals files to sell $150M in common stock, 1.6M for holders
Subscribe for More Information
May 13, 2015
16:39 EDTADMSAdamas Pharmaceuticals sees Namzaric launching in coming months
During its Q1 earnings report, Adamas (ADMS) stated, "In the coming months, we look forward to expanding our wholly-owned product pipeline with the initiation of a phase 2 clinical trial of ADS-5102 for a second CNS-related indication, completing enrollment in one of two ongoing phase 3 trials assessing ADS-5102 for the treatment of LID, and the U.S. launch of Namzaric by our collaborator, Actavis (ACT)."
16:03 EDTADMSAdamas Pharmaceuticals reports Q1 EPS (69c), consensus (74c)
Reports Q1 revenue $226,000 vs. $176,000 last year. Reports $145M in cash, cash equivalents, and marketable securities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use